65 - References

References
Addictions and substance misuse
CHAPTER 4
References
Couchman L, et al. Amisulpride and sulpiride interfere in the CEDIA DAU buprenorphine test. Ann Clin Psychiatry 2008; 45 Suppl 1.
Merative US L.P. Micromedex. 2024; https://www.micromedexsolutions.com/home/dispatch/.
Substance Abuse and Mental Health Services Administration (US). Substance Abuse: Clinical Issues in Intensive Outpatient Treatment.
Treatment Improvement Protocol (TIP) Series, No. 47. 2006.
Vandevenne M, et al. Detection time of drugs of abuse in urine. Acta Clin Belg 2000; 55:323–333.
Brahm NC, et  al. Commonly prescribed medications and potential false-­positive urine drug screens. Am J Health Syst Pharm 2010;
67:1344–1350.
Saitman A, et al. False-­positive interferences of common urine drug screen immunoassays: a review. J Anal Toxicol 2014; 38:387–396.
Liu CH, et al. False positive ketamine urine immunoassay screen result induced by quetiapine: a case report. J Formos Med Assoc 2017;
116:720–722.
Shoptaw SJ, et al. Treatment for amphetamine psychosis. Cochrane Database Syst Rev 2009; 1:CD003026.
Farley TM, et al. False-­positive phencyclidine (PCP) on urine drug screen attributed to desvenlafaxine (Pristiq) use. BMJ Case Rep 2017;
2017:bcr-­2017-­222106.
Johns A. Psychiatric effects of cannabis. Br J Psychiatry 2001; 178:116–122.
Hall W, et al. Long-­term cannabis use and mental health. Br J Psychiatry 1997; 171:107–108.
Murray RM, et al. Traditional marijuana, high-­potency cannabis and synthetic cannabinoids: increasing risk for psychosis. World Psychiatry
2016; 15:195–204.
Marconi A, et  al. Meta-­analysis of the association between the level of cannabis use and risk of psychosis. Schizophr Bull 2016;
42:1262–1269.
Arseneault L, et al. Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry 2004; 184:110–117.
Budney AJ, et al. Review of the validity and significance of cannabis withdrawal syndrome. Am J Psychiatry 2004; 161:1967–1977.
Bonnet U, et al. The cannabis withdrawal syndrome: current insights. Subst Abuse Rehabil 2017; 8:9–37.
Schröck A, et al. Pharmacokinetics of GHB and detection window in serum and urine after single uptake of a low dose of GBL – an
­experiment with two volunteers. Drug Test Anal 2014; 6:363–366.
Busardò FP, et al. Ultra-­high performance liquid chromatography tandem mass spectrometry (UHPLC-­MS/MS) for determination of GHB,
precursors and metabolites in different specimens: application to clinical and forensic cases. J Pharm Biomed Anal 2017; 137:123–131.
Bowden-­Jones O, et al. on behalf of the NEPTUNE Expert Group. Guidance on the Clinical Management of Acute and Chronic Harms of
Club Drugs and Novel Psychoactive Substances. London: Novel Psychoactive Treatment UK Network (NEPTUNE); 2015.
Chen WY, et al. Gender differences in subjective discontinuation symptoms associated with ketamine use. Subst Abuse Treat Prev Policy
2014; 9:39.
Critchlow DG. A case of ketamine dependence with discontinuation symptoms. Addiction 2006; 101:1212–1213.
Adamowicz P, et  al. Urinary excretion rates of ketamine and norketamine following therapeutic ketamine administration: method and
­detection window considerations. J Anal Toxicol 2005; 29:376–382.
Passie T, et al. The pharmacology of lysergic acid diethylamide: a review. CNS Neurosci Ther 2008; 14:295–314.
Gov.UK Advisory Council on Misuse of Drugs. Research and analysis: ACMD advice on 2-­benzyl benzimidazole and piperidine benzimidazolone
opioids (accessible version). 2024; https://www.gov.uk/government/publications/acmd-­advice-­on-­2-­benzyl-­benzimidazole-­and-­piperidine-­
benzimidazolone-­opioids/acmd-­advice-­on-­2-­benzyl-­benzimidazole-­and-­piperidine-­benzimidazolone-­opioids-­accessible-­version.
Advisory Council on the Misuse of Drugs. ACMD report – misuse of fentanyl and fentanyl analogues. 2020; https://assets.publishing.service.
gov.uk/media/5e0f5952e5274a0f9bccd774/ACMD_Report_-­_Misuse_of_fentanyl_and_fentanyl_analogues.pdf.
Tebo C, et al. Suspected synthetic cannabinoid receptor agonist intoxication: does analysis of samples reflect the presence of suspected agents?
Am J Emerg Med 2019; 37:1846–1849.
Malaca S, et al. Pharmacology and toxicology of xylazine: quid novum? Eur Rev Med Pharmacol Sci 2023; 27:7337–7345.
Truver MT, et al. A quantitative LC-­MS/MS analysis of xylazine, p-­fluorofentanyl, fentanyl and fentanyl-­related compounds in postmortem
blood. J Chromatogr B Analyt Technol Biomed Life Sci 2024; 1237:124059.
Moeller KE, et al. Clinical interpretation of urine drug tests: what clinicians need to know about urine drug screens. Mayo Clin Proc 2017;
92:774–796.